Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
60,041
result(s) for
"Epidemics Prevention"
Sort by:
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia
In a phase 3 noninferiority trial, one dose of a new meningococcal vaccine (NmCV-5) elicited immune responses similar to those of MenACWY-D for the four serotypes in common and additional immune responses for serogroup X.
Journal Article
Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay–Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays
Emerging evidence shows correlation between the presence of neutralization antibodies (nAbs) and protective immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently available commercial serology assays lack the ability to specifically identify nAbs. An enzyme-linked immunosorbent assay-based nAb assay (GenScript cPass neutralization antibody assay) has recently received emergency use authorization from the Food and Drug Administration.
To evaluate the performance characteristics of this assay and compare and correlate it with the commercial assays that detect SARS-CoV-2-specific immunoglobulin G (IgG).
Specimens from SARS-COV-2 infected patients (n = 124), healthy donors obtained prepandemic (n = 100), and patients with non-coronavirus disease 2019 (COVID-19) respiratory infections (n = 92) were analyzed using this assay. Samples with residual volume were also tested on 3 commercial serology platforms (Abbott, Euroimmun, Siemens). Twenty-eight randomly selected specimens from patients with COVID-19 and 10 healthy controls were subjected to a plaque reduction neutralization test.
The cPass assay exhibited 96.1% (95% CI, 94.9%-97.3%) sensitivity (at >14 days post-positive PCR), 100% (95% CI, 98.0%-100.0%) specificity, and zero cross-reactivity for the presence of non-COVID-19 respiratory infections. When compared with the plaque reduction assay, 97.4% (95% CI, 96.2%-98.5%) qualitative agreement and a positive correlation (R2 = 0.76) was observed. Comparison of IgG signals from each of the commercial assays with the nAb results from plaque reduction neutralization test/cPass assays displayed greater than 94.7% qualitative agreement and correlations with R2 = 0.43/0.68 (Abbott), R2 = 0.57/0.85 (Euroimmun), and R2 = 0.39/0.63 (Siemens), respectively.
The combined data support the use of cPass assay for accurate detection of the nAb response. Positive IgG results from commercial assays associated reasonably with nAbs presence and can serve as a substitute.
Journal Article
Deadliest enemy : our war against killer germs
Infectious disease has the terrifying power to disrupt everyday life on a global scale, overwhelming public and private resources and bringing trade and transportation to a halt. In today's world, it's easier than ever to move people, animals, and materials around the planet, but the same advances that make modern infrastructure so efficient have made epidemics and even pandemics nearly inevitable. So what can -- and must -- we do in order to protect ourselves? Drawing on the latest medical science, case studies, and policy research, Deadliest enemy explores the resources and programs we need to develop if we are to keep ourselves safe from infectious disease.
Book
AI-powered epidemic control: Deepseek’s role in global health resilience
DeepSeek, an AI-driven platform, revolutionizes epidemic management through early warning systems, trend prediction, treatment optimization, and public consultation. By integrating multi-source real-time data (epidemiological, social media, mobility) with deep learning models (LSTM, Transformers) and explainable decision frameworks,, it enhances public health responsiveness. Challenges include data privacy and model accuracy, but its potential to fortify global health resilience is transformative.
Journal Article
Global pandemic threats : a reference handbook
\"Global Pandemic Threats: A Reference Handbook provides all-encompassing coverage that introduces key concepts and traces the history of pandemics, enabling readers to grasp the complexity of the global problem and the difficulties of executing effective solutions. Written in an easy-to-understand manner, it provides a \"go-to\" resource that systematically addresses dozens of diseases of the past as well as re-emergent or newly emerging pathogens that have the potential of becoming pandemics. The book's extensive coverage of past pandemics includes bubonic plague, cholera, influenza, measles, smallpox, tuberculosis, typhoid fever, and yellow fever, and the re-emergence of malaria, measles, pertussis (whooping cough), poliomyelitis, and other contagious diseases. It discusses a broad range of newly emerging viral threats, such as AIDS/HIV, avian flu, anthrax, botulism, Ebola, E. coli, Gulf War syndrome, hanta virus, Lassa virus, Lyme disease, Marburg virus, MERS, MRSA, Ricin, Sin Nombre virus (SNV), and West Nile virus. The work offers perspectives from individuals interested and involved in the fight, including medical professionals and health care workers; profiles of key organizations and persons; a helpful timeline of past and present pandemic outbreaks; and a glossary of key terms and concepts.\" -- Publisher's description
Book
Ebola: lessons learned and future challenges for Europe
The Ebola virus epidemic has topped media and political agendas for months; several countries in west Africa have faced the worst Ebola epidemic in history. At the beginning of the disease outbreak, European Union (EU) policies were notably absent regarding how to respond to the crisis. Although the epidemic is now receding from public view, this crisis has undoubtedly changed the European public perception of Ebola virus disease, which is no longer regarded as a bizarre entity confined in some unknown corner in Africa. Policy makers and researchers in Europe now have an opportunity to consider the lessons learned. In this Personal View, we discuss the EU's response to the Ebola crisis in west Africa. Unfortunately, although ample resources and opportunities for humanitarian and medical action existed, the EU did not use them to promote a rapid and well coordinated response to the Ebola crisis. Lessons learned from this crisis should be used to improve the role of the EU in similar situations in the future, ensuring that European aid can be effectively deployed to set up an improved emergency response system, and supporting the establishment of sustainable health-care services in west Africa.
Journal Article
Global catastrophic biological risks
This volume focuses on Global Catastrophic Biological Risks (GCBRs), a special class of infectious disease outbreaks or pandemics in which the combined capacity of the worlds private and government resources becomes severely strained. These events, of which the 1918 influenza pandemic is emblematic, cause severe disruptions in the normal functioning of the world, exact heavy tolls in terms of morbidity and mortality, and lead to major economic losses. GCBRs can be caused by any type of microorganism, and myriad contextual factors can influence their impact. Additionally, there are cascading questions that arise in connection with GCBR prediction, preparation, and response. This book gathers contributions from thought leaders who discuss the multi-faceted approaches needed in order to address this problem. From understanding the special characteristics of various microbes to financing challenges, the volume provides an essential primer on a neglected but highly relevant topic. Physicians, scientists, policymakers, public health practitioners and anyone with an interest in the field of pandemics, emerging infectious disease, biosecurity, and global health security will find it a valuable and insightful resource.
Book
Effect of the “Normalized Epidemic Prevention and Control Requirements” on hospital-acquired and community-acquired infections in China
Background
No studies have yet reported the effect of prevention and control measures, which were implemented to combat COVID-19, on the prevention and control of common HAIs. We aimed to examine the effect of the “Normalized Epidemic Prevention and Control Requirements” (implemented in May 2020) by comparison of hospital-acquired infections (HAIs) and community-acquired infections (CAIs) in China during 2018, 2019, and 2020.
Methods
Data of inpatients before and after implementation of new requirements were retrospectively analyzed, including infection rate, use of alcohol-based hand cleaner, anatomical sites of infections, pathogen species, infection by multi-drug resistant species, and use of different antibiotics.
Results
The HAI rate was significantly higher in 2020 than in 2018 and 2019 (
P
< 0.05), and the CAI rate was significantly higher in 2019 and 2020 than in 2018 (
P
< 0.001). Lower respiratory tract infections were the most common HAI during all years, with no significant changes over time. Lower respiratory tract infections were also the most common CAI, but were significantly more common in 2018 and 2019 than 2020 (
P
< 0.001). There were no changes in upper respiratory tract infections among HAIs or CAIs. Most HAIs and CAIs were from Gram-negative bacteria, and the percentages of fungal infections were greater in 2019 and 2020 than 2018. MRSA infections were more common in 2020 than in 2018 and 2019 (
P
< 0.05). The utilization rate and usage days of antibiotics decreased over time (
P
< 0.001) and the culture rate of microbial specimens before antibiotic usage increased over time (
P
< 0.001).
Conclusions
The new prevention and control requirements provided important benefits during the COVID-19 pandemic. However, their effects on HAIs were not obvious.
Journal Article